Editor’s Choice: A New Dystonia Center of Excellence, A Call for Sickle Cell Blood Donors, and a New Treatment Target for Glioblastoma

Happy Friday! A tropical storm system will be traveling up through the mid-Atlantic this weekend, bringing wind and rain. Hunker down! This week, we have stories on Duke University being…

Continue Reading Editor’s Choice: A New Dystonia Center of Excellence, A Call for Sickle Cell Blood Donors, and a New Treatment Target for Glioblastoma
Patient Worthy’s One-Year-Checkup on Victoria Gray, the First Sickle Cell Disease Patient to Receive CRISPR in the US
source: pixabay.com

Patient Worthy’s One-Year-Checkup on Victoria Gray, the First Sickle Cell Disease Patient to Receive CRISPR in the US

   CRISPR is a gene-editing technique that has revolutionized the medical world with its approach to making precise changes in DNA. CRISPR found its match in 35-year-old Victoria Gray of…

Continue Reading Patient Worthy’s One-Year-Checkup on Victoria Gray, the First Sickle Cell Disease Patient to Receive CRISPR in the US
Emmaus Life Sciences Makes Drug For Sickle Cell Disease Free For Those That Can’t Pay
source: pixabay.com

Emmaus Life Sciences Makes Drug For Sickle Cell Disease Free For Those That Can’t Pay

As reported in PR NewsWire;  in an effort to help the entirety of the sickle cell disease community, Emmaus Life Sciences, Inc has announced a program that will provide their…

Continue Reading Emmaus Life Sciences Makes Drug For Sickle Cell Disease Free For Those That Can’t Pay
Use of Tissue Type Plasminogen Activator in Sickle Cell Disease Patients Experiencing Stroke
source: pixabay.com

Use of Tissue Type Plasminogen Activator in Sickle Cell Disease Patients Experiencing Stroke

by Lauren Taylor from In The Cloud Copy Sickle cell disease or SCD is a type of red blood cell disorder in which the normally round red blood cells are…

Continue Reading Use of Tissue Type Plasminogen Activator in Sickle Cell Disease Patients Experiencing Stroke
Experimental Treatment for Sickle Cell Disease Earns Orphan Drug Designation in the EU
source: pixabay.com

Experimental Treatment for Sickle Cell Disease Earns Orphan Drug Designation in the EU

According to a story from Street Insider, the biopharmaceutical company Forma Therapeutics Holdings, Inc., recently announced that its investigational therapy candidate FT-4202 has earned Orphan Drug designation from the European…

Continue Reading Experimental Treatment for Sickle Cell Disease Earns Orphan Drug Designation in the EU